Kornimate/medical-research-clean huggingface dataset:
efficacy of ipl treatment of dry eye and ocular rosacea

Conditions: Ocular Rosacea; Dry Eye

Summary: dry eye disease (ded) is a common condition that causes ocular discomfort and reduces visual acuity. the two categories of ded are evaporative dry eye and aqueous deficient dry eye. both conditions can involve pathology of the meibomian glands, lacrimal glands, lids, tear film and surface cells. meibomian gland dysfunction (mgd) is the leading cause of evaporative dry eye and contributes to aqueous deficient dry eye. the goal of mgd therapy is to provide long term improvement of symptoms for patients by improving the quality of meibum, increasing meibum flow, improving tear film stability and decreasing inflammation. commonly used therapies include preservative free drops, omega-3 fatty acid supplementation, topical cyclosporine, serum tears, topical azithromycin, oral doxycycline, moisture chambers, intraductal probing, lib margin exfoliation, automated thermal pulsation, warm compresses, among other. despite this variety of symptoms, patients often do not experience complete or long term relief of symptoms. forced meibomian gland expression (mgx) has been shown to be an effective method of rehabilitating meibomian glands and improving dry eye symptoms. the eyelid margins are forcefully compressed to express gland contents. research has shown improvement in patient symptoms with the use of mgx. intense pulsed light (ipl) have been used in dermatology to treat various conditions. patients with ded who have tried other therapies and found no relief, often resort to ipl as a last resort. research has shown ipl alone may be effective in improving patient symptoms. in addition, such studies have failed to show significant adverse events with the use of ipl. here, we propose a prospective, randomized, case controlled clinical pilot study to examine the efficacy for both subjective and objective measures. 20 patients with ded will be recruited and will be randomly assigned to one of two groups: mgx alone or mgx with ipl. objective measures will include tear cytokine levels, impression cytology, meibography, tear osmolarity and others. subjective measures will include quality of life screening tools. we hypothesize that the use of mgx with ipl will lead to greater improvement in subjective dry eye symptoms and objective measures. given the lack of adverse effects reported in the literature, we do not anticipate adverse effects in our study. rochester staff drs. faustch and bourne are providing clinical research advice but have no contact with subjects or biospecimens.


Eligibility criteria:
dry eye of moderate severity with ocular rosacea diagnosed by ophthalmologist. no contraindications of severe ocular surface disease or inability to be safely treated with ipl. dry eye symptoms must be alleviated with topical anesthetic. no gvhd, stevens johnson, active allergic conjunctivitis or other conjunctivitis, alkali burn history. subjects must have at least 50% meibomian glands viable on meibography and no new treatments for dry eye in the past 6 months. contact lenses and refractive surgery is okay.

Keywords: intense pulsed light
efficacy and safety of hydromorphone hydrochloride extended-release compared to placebo in subjects with persistent pain

Conditions: Chronic Non-Malignant Pain

Summary: the objective of this study is to assess the efficacy and safety of 8 mg hydromorphone hydrochloride extended-release.

the primary efficacy objective of this study is to compare the time to emergence of inadequate analgesia of 8 mg hydromorphone hydrochloride extended-release taken once every 24 hours versus placebo in the treatment of patients with persistent pain who require an opioid medication for control of their pain.

Eligibility criteria:
inclusion criteria: * persistent, moderate-to-severe noncancer related pain requiring continuous analgesia for weeks to months, or longer, who are currently taking 20 to 40 mg of oxycodone or opioid equivalents per day for control of their persistent pain and who are willing to accept the possibility of receiving placebo during the double-blind phase exclusion criteria: * patients already receiving opioid medication at an average total daily dose greater than 40 mg of oxycodone or opioid equivalents during the last week prior to study entry. other protocol-specific exclusion/inclusion criteria may apply.

Keywords: chronic non-malignant pain, opioid
evaluation of catheter associated urinary tract infection between metal alloy coated catheter and conventional latex catheter in critically ill patients

Conditions: Sepsis; Urosepsis; Intensive Care Unit

Summary: this is a prospective single blinded randomized trial to evaluate the incidence of catheter associated urinary tract infection (cauti) between latex catheter and metal alloy coated catheter among intensive care unit (icu) patients. cauti has a few definitions, in this study, we will follow the latest central of disease control (cdc) guideline definition of cauti in january 2022. this study involves 100 patients who meet the inclusion and exclusion criteria that have been set. the patients will be divided into group a and group b and two types of catheters will be given out to the healthcare workers according to the randomization. data collection involves demographic, medical and laboratory data and will be documented in the tables provided. all data will be collected from day of urinary catheterization in icu until patients discharge or die or maximum of 14 days in icu or develop cauti or abuti or whichever that occurred earlier. patients who died within 48 hours of catheter insertion, will be considered as drop-out. data that has been extrapolated from this study will then give us an insight regarding the best type of catheter to avoid cauti, risk factors associated with cauti and to determine length of icu stay and icu morbidity with patients who have cauti. this study proves to be important in reducing the overall healthcare associated infection in the icu setting.


Eligibility criteria:
inclusion criteria 1. adult more than 18 years old 2. indwelling urinary catheter more than 48 hours exclusion criteria 1. community urosepsis 2. chronic kidney disease and end stage renal failure 3. suprapubic catheter 4. patient with dependent urinary catheter 5. pregnant ladies 6. congenital urinary tract abnormality 7. surgical procedure involving urinary tract 8. moribound patient or expected to die within 24 hours 9. discharged to ward within 48 hours 10. latex allergy
autoset t versus cpap therapy, a comparison of titration and therapy

Conditions: Sleep Apnea Syndromes

Summary: part 1.comparison of manual pressure titration in laboratory of sleep disorders with autoset t apap device from resmed. hypothesis: there is no difference in efficiency between manual and automatical titration. part 2. comparison of cpap and apap therapy in the home while 3 month by questionaire and device data. hypothesis: there is a difference in compliance and efficiency between cpap and apap mode.

a cross over, simple blind study design has been created for a controlled trial to compare pressure titration and therapy with the autoset t device. part 1: after a baseline polysomnography (psg) a selected group of patients with obstructive sleep apnea will be titrated in two more nights in a sleep lab under apap mode and cpap mode. we compare the sleep quality and the ahi, oxygen saturation, leakage. part 2: over a time range of 12 weeks the patients got two kinds of therapy modes at home: cpap and apap (each six weeks. we compare the objective and subjective therapy by compliance, device data, epworth sleepiness scale, pittsburgh sleep quality index (psqi, german version).

Eligibility criteria:
inclusion criteria: * age from 18 to 80 years exclusion criteria: * pregnancy * insomnia * consumption of soporifics * pulmonal or cardial diseases * operation advised by ear, nose and throat specialist * missing linguistic skills in german

Keywords: cpap apap sleep apnea
glucose-dependent insulinotropic polypeptide as a safeguard against hypoglycemia in patients with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: in the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (gip) may be utilized as a safeguard against hypoglycemia in patients with t1d.


Eligibility criteria:
inclusion criteria: * caucasian men * body mass index between 20-27 kg/m\^2 * t1d (diagnosed according to the criteria of the world health organization) with hba1c\<69 mmol/l (\<8,5%) * t1d duration between 2-20 years * stimulated c-peptide ≤ 100 pmol/ml) * treatment with a stable basal bolus or insulin pump regimen ≥ 3 months * informed consent exclusion criteria: * anemia (hemoglobin below normal range) * liver disease (alat and/or asat \>2 times normal values) or history of hepatobiliary disorder * nephropathy (serum creatinine above normal range and/or albuminuria) * allergy or intolerance to ingredients included in the standardized meals * prior myocardial infarction or other cardiac events * any physical or psychological condition that the investigator fells would interfere with trial participation * treatment with any glucose-lowering drugs beside insulin

Keywords: diabetes mellitus, type 1 hypoglycemia gastric inhibitory polypeptide glucagon incretin
comparison of two pen systems in patients with diabetes treated with insulin

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Delivery Systems

Summary: this trial is conducted in europe. the aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes mellitus for at least 12 months * adults at least 18 years * children/adolescents between 9-18 years * hba1c lesser than or equal to 11.0% exclusion criteria: * known or suspected alcohol or drug abuse * patients who are not able to read the user manual (may wear glasses if needed) * hypoglycaemic unawareness as judged by the investigator * visual and/or dexterity impairments as judged by the investigator
safety and pharmacokinetic study of eo9(intravesical instillation)

Conditions: Bladder Cancer

Summary: the purpose of this study is to evaluate the safety and pharmacokinetics (pk) of intravesical instillation of eo9 in patients with non-muscle invasive bladder cancer (nmibc).


Eligibility criteria:
inclusion criteria: * patients who are clinically diagnosed as having stage ta, t1, histological grade g1, g2 urothelial carcinoma of the bladder * patients who are confirmed to be urinary cytology negative (class i, class ii) within 4 weeks prior to the present turbt. * p.s : 0-2 according to the ecog. exclusion criteria: * patients with a primary and solitary tumor. * cis lesions in the bladder or a history thereof. * grade 3 disease or a history thereof. * patients experiencing recurrence within 3 months following turbt for prior nmibc. * patients having stage t1 and high-grade disease. * invasive cancer of t2 or greater, with definite lymph node or other organ metastasis, or a history thereof. * patients who received intravesical chemotherapy/immunotherapy treatment within 6 months prior to the present turbt. * patients who underwent systemic chemotherapy or radiotherapy whose field of exposure included the bladder. * patients with suspected bladder perforation at the time of the present turbt. * a complication of a malignant tumor of the upper urinary tract or urethra, or a history thereof. * malignancy within 5 years other than nmibc (except thyroid cancer) * a serious viral or bacterial infection within the last 4 weeks.

Keywords: bladder cancer eo9 apaziquone
enose-tb: electronic nose for tuberculosis screening

Conditions: Tuberculosis

Summary: an electronic-nose (e-nose) is being investigated as a diagnostic tool for tuberculosis by examining exhaled breath of the patients. universitas gadjah mada has developed an e-nose device for tb diagnostic tool. here the investigators test the device in order to analyze the sensitivity and specificity electronic-nose as a screening tool for tuberculosis particularly in remote area. various factors (gender, age, race, and location) are considered in the algorithm training to develop an inclusive enose. access barriers, especially those faced by women, are also assessed.

the study population consists of 2 groups: group 1 - presumptive tb patients. group 2 - residents of area with high risk of tb. study participants provide written informed consent. the participants are asked to breathe normally using a mask for 2 times then inhale and exhale in a forced expiratory volume to the air collecting bag until the collecting bag is full (two times). the collecting bag is sealed and connected to the e-nose machine via a collecting hose and hepa-filter protecting the e-nose from microbes. the breath pattern will be recorded in the e-nose device, which is connected to a laptop that will display the recorded breath pattern. other data are collected: clinical symptoms, results of chest x-ray, smear microscopic, and xpert mtb/rif examinations. demographic (gender, age, race, and location) and clinical data (symptoms, physical examination, laboratory examinations) are collected. access barriers, especially for women, are also assessed through questionnaire and interviews.

Eligibility criteria:
- inclusion criteria: validation phase (group 1): * adult and children * suspected of having tb * agree to participate in the study * able to produce exhaled air samples * able to produce samples for xpert mtb/rif examination screening phase (group 2): * adult and children * agree to participate in the study * able to produce exhaled air samples * currently not in tb treatment - exclusion criteria * invalid measurements of breath tests * incomplete cxr data * missing specimens * unable to breath normally for 2 minutes due to respiratory illness

Keywords: electronic-nose breath test tuberculosis screening gender remote area
thumb muscle thickness and strength in cmc osteoarthritis

Conditions: Osteoarthritis

Summary: a total of 34 patients aged between 50-80 years, diagnosed with first carpometacarpal joint osteoarthritis based on hand radiographs taken within the last 3 months, will be included in the study from the physical therapy and rehabilitation outpatient clinic. sociodemographic data such as age, gender, height, weight, and bmi will be recorded. based on their current radiographs, patients will be classified into two groups according to the eaton-littler classification: stage 1-2 (early stage) and stage 3-4 (advanced stage). pain levels will be assessed using the visual analog scale (vas). hand grip strength will be evaluated with a jamar hand dynamometer, and pinch grip strength will be assessed with a jamar pinch meter. the thicknesses of the abductor pollicis brevis, first dorsal interosseous, and opponens pollicis muscles will be measured using ultrasound. all assessments will be performed separately for the dominant and non-dominant hands.


Eligibility criteria:
inclusion criteria: * patients aged 50-80 years. * diagnosed with first carpometacarpal joint osteoarthritis. * presence of a hand radiograph taken within the last 3 months. * volunteered to participate in the study. exclusion criteria: * refusal to participate in the study. * use of medications that may suppress osteoarthritis flares. * presence of rheumatologic diseases causing peripheral joint involvement. * history of fractures or surgeries involving the first carpometacarpal joint. * presence of psychiatric disorders. * presence of cognitive impairments that could hinder understanding or performance of study-related tasks.
drug user internet and mobile tech use

Conditions: Drug Abuse Illicit

Summary: the purpose of this exploratory study is to examine factors associated with frequency and type of internet and mobile technology use among illegal drug users, specifically use of internet and text-messaging to obtain health care information and engage in health care utilization, specifically human immunodeficiency virus (hiv) prevention and treatment services. we will target high drug activity neighborhoods in new york city and enroll participants recruited through targeted street outreach. all participants (n=336) will undergo an audio computer-assisted self-interview (acasi) that will assess sociodemographics, health care access and utilization, sex/drug use behavior, health status, and characteristics of general and health-related internet/mobile technology use including factors that promote or hinder use. participants identified as using the internet ≥1/month (n=151) will return for a 4-week acasi to report on use of the pilot website (which will largely display information currently available in the community in print/ pamphlet/ video form).

at the enrollment visit participants deemed eligible after screening will be consented, and given a 30 minute baseline acasi survey. at the end of the baseline visit, those participants who reported internet use at least 1x/month (in the past month) will be offered participation in the pilot website evaluation component. for this component, participants will be instructed on how to use an educational website with health resources. their use of the website will be tracked. they will be given an appointment to return in 4-weeks for a follow up survey at the pharmacy and a 2-week locator call.

Eligibility criteria:
inclusion criteria: * any lifetime illegal drug use * age \> 18 exclusion criteria: * none

Keywords: internet and mobile technology use history of drug use injection drug user (idu) syringe customers
fu zheng jie du hua yu principle for treatment of severe hbv related hepatocellular carcinoma (fzjdhypftoshbvhcc)

Conditions: Hepatocellular Carcinoma

Summary: the treatment of hbv related hepatocellular carcinoma has always been a worldwide problem. the aim of this study is to alleviate the progression of hepatitis b related hepatocellular carcinoma by the chinese medicine "fu zheng jie du hua yu" principle.


Eligibility criteria:
inclusion criteria: * meet the criteria of hepatocellular carcinoma * ages eligible for study: ≤75 years old; * informed consent from the patient. exclusion criteria: * serious problem of heart, lung, or kidney with severe dysfunction; * pregnant or child breast feeding women; * mental or cognitive disorders; * participating in other drug trials; * who are allergic to the study drug
real-world effectiveness of combination therapies in primary care asthma management

Conditions: Asthma

Summary: the purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (bdp/for; fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (fp/sal; seretide® 125) in matched asthma patients switching to bdp/for following treatment with fp/sal in normal clinical practice compared with patients not switched.


Eligibility criteria:
inclusion criteria: * aged: * 18-60 years: * 61-80 years who are never-smokers * evidence of asthma: * a diagnostic code for asthma, or * ≥2 prescriptions for asthma at different points in time during the prior year * baseline fp/sal therapy: * ≥2 prescription for ics/laba therapy as fp/sal (seretide® 125). exclusion criteria: * any chronic respiratory disease other than asthma * are receiving maintenance oral steroid therapy during baseline period.

Keywords: asthma combination therapy primary care management switch ics/laba fostair seretide
lora-pita iv general investigation

Conditions: Status Epilepticus

Summary: secondary data collection:to confirm the effectiveness and safety profiles under the actual medical practice of lora-pita in japan.

to confirm the effectiveness and safety profiles under the actual medical practice of lora-pita for status epilepticus patients in japan.

Eligibility criteria:
inclusion criteria: patients administered lorazepam in accordance with the indication (for status epilepticus) and have no history of using this drug.

Keywords: status epilepticus; lorazepam; lora-pita; ativan
occupational exposure to human papilloma virus (hpv) and prophylactic vaccination

Conditions: Papillomavirus Vaccines

Summary: currently there are no standards for healthcare worker vaccination with the hpv, gardasil-9 vaccine. for health care workers, the cdc only recommends for vaccination against hepatitis b, influenza virus, measles, mumps and rubella (mmr), chickenpox (varicella), tetanus, diptheria, and pertussis (tdap), and meninogococcal infections6

initial antibody titers will be measured immediately prior to initial vaccination (month 0). this will entail a blood-draw sample (less than 1 teaspoon) that will be sent to focus labs for evaluation. this will be paid for by funding received from merck. the three-dose vaccination schedule will be followed with injections at month 0, 2, and 6. gardasil 9 dosing will be per the recommended and approved labeled guidelines. post-vaccination titers would be measured at month 7, which is in alignment with the methods of previous studies. this will entail a blood-draw sample (less than 1 teaspoon) that will be sent to focus labs for evaluation.

Eligibility criteria:
inclusion criteria: * • actively practicing attending surgeon in the field of otolaryngology, general surgery, urology, or obstetrics-gynecology employed by evms or credentialed by chkd and/or sngh. or • current residents of evms otolaryngology, general surgery, urology, or obstetrics-gynecology programs exclusion criteria: * • age 26 or younger * age over 69 * hypersensitivity to vaccine component * history of severe allergic or hypersensitivity reactions to yeast * history of previous hpv vaccination with 9 valent vaccine * pregnant * moderate or severe acute illness

Keywords: human papilloma virus